Provided By PR Newswire
Last update: Jul 22, 2025
NEW YORK, July 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Jasper Therapeutics, Inc. ("Jasper" or the "Company") (NASDAQ: JSPR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read more at prnewswire.comNASDAQ:JSPR (9/5/2025, 8:25:58 PM)
2.72
+0.03 (+1.12%)
Find more stocks in the Stock Screener